JP2017506227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506227A5 JP2017506227A5 JP2016549715A JP2016549715A JP2017506227A5 JP 2017506227 A5 JP2017506227 A5 JP 2017506227A5 JP 2016549715 A JP2016549715 A JP 2016549715A JP 2016549715 A JP2016549715 A JP 2016549715A JP 2017506227 A5 JP2017506227 A5 JP 2017506227A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- medicament
- pembrolizumab
- dose
- axitinib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 229960002621 pembrolizumab Drugs 0.000 claims 11
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical group CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 229960003005 axitinib Drugs 0.000 claims 9
- 108091008605 VEGF receptors Proteins 0.000 claims 5
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims 5
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 3
- 229940124060 PD-1 antagonist Drugs 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 210000003989 endothelium vascular Anatomy 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000002991 immunohistochemical analysis Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019170177A JP6894952B2 (ja) | 2014-02-04 | 2019-09-19 | 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461935809P | 2014-02-04 | 2014-02-04 | |
| US61/935,809 | 2014-02-04 | ||
| PCT/US2015/014212 WO2015119930A1 (en) | 2014-02-04 | 2015-02-03 | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019170177A Division JP6894952B2 (ja) | 2014-02-04 | 2019-09-19 | 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506227A JP2017506227A (ja) | 2017-03-02 |
| JP2017506227A5 true JP2017506227A5 (enExample) | 2018-03-15 |
| JP6591428B2 JP6591428B2 (ja) | 2019-10-16 |
Family
ID=52463238
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549715A Active JP6591428B2 (ja) | 2014-02-04 | 2015-02-03 | 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ |
| JP2019170177A Active JP6894952B2 (ja) | 2014-02-04 | 2019-09-19 | 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ |
| JP2021093346A Pending JP2021130709A (ja) | 2014-02-04 | 2021-06-03 | 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019170177A Active JP6894952B2 (ja) | 2014-02-04 | 2019-09-19 | 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ |
| JP2021093346A Pending JP2021130709A (ja) | 2014-02-04 | 2021-06-03 | 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10570202B2 (enExample) |
| EP (3) | EP3971209A1 (enExample) |
| JP (3) | JP6591428B2 (enExample) |
| KR (3) | KR20230023810A (enExample) |
| CN (2) | CN105960415A (enExample) |
| AU (1) | AU2015214390B2 (enExample) |
| BR (1) | BR112016017256A2 (enExample) |
| CA (2) | CA2937521C (enExample) |
| CY (2) | CY1121374T1 (enExample) |
| DK (1) | DK3102605T3 (enExample) |
| EA (1) | EA201691376A1 (enExample) |
| ES (2) | ES2710211T3 (enExample) |
| HU (2) | HUE041469T2 (enExample) |
| IL (2) | IL311399A (enExample) |
| MX (1) | MX386604B (enExample) |
| PL (2) | PL3498734T3 (enExample) |
| PT (2) | PT3102605T (enExample) |
| SG (2) | SG10201806656UA (enExample) |
| SI (2) | SI3102605T1 (enExample) |
| TR (1) | TR201901507T4 (enExample) |
| TW (1) | TWI663983B (enExample) |
| WO (1) | WO2015119930A1 (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| US20160303231A1 (en) * | 2013-12-11 | 2016-10-20 | Robert Iannone | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor |
| LT3081576T (lt) | 2013-12-12 | 2019-10-25 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas |
| EP3102604B1 (en) | 2014-02-04 | 2020-01-15 | Pfizer Inc | Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer |
| DK3102605T3 (en) | 2014-02-04 | 2019-02-25 | Pfizer | COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATMENT OF CANCER |
| CN106255510A (zh) * | 2014-03-05 | 2016-12-21 | 百时美施贵宝公司 | 使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌 |
| US10800846B2 (en) | 2015-02-26 | 2020-10-13 | Merck Patent Gmbh | PD-1/PD-L1 inhibitors for the treatment of cancer |
| EP3283882B2 (en) | 2015-04-17 | 2024-10-16 | Merck Sharp & Dohme LLC | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
| US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
| CR20180318A (es) | 2015-12-14 | 2018-09-19 | Macrogenics Inc | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas |
| CN105669864B (zh) | 2015-12-23 | 2018-10-16 | 杭州尚健生物技术有限公司 | 抗人程序性死亡受体1抗体及其制备方法和用途 |
| CN107126563B (zh) * | 2016-02-26 | 2021-09-10 | 博生吉医药科技(苏州)有限公司 | 含低剂量阻断vegf信号通路的抗体的组合物及其用途 |
| WO2017212442A1 (en) * | 2016-06-10 | 2017-12-14 | Novartis Ag | Therapeutic uses of a c-raf inhibitor |
| JP7083760B2 (ja) | 2016-06-29 | 2022-06-13 | テサロ， インコーポレイテッド | 卵巣癌の治療方法 |
| WO2018044888A1 (en) * | 2016-08-29 | 2018-03-08 | Chen James C | Tumor vaccination systems, devices, and methods |
| WO2018057303A1 (en) * | 2016-09-26 | 2018-03-29 | Imclone Llc | Combination therapy for cancer |
| WO2018058125A1 (en) | 2016-09-26 | 2018-03-29 | Ensemble Group Holdings | Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems |
| IL265762B2 (en) | 2016-10-06 | 2024-04-01 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
| TWI764943B (zh) | 2016-10-10 | 2022-05-21 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 |
| CN117586401A (zh) | 2017-01-20 | 2024-02-23 | 大有华夏生物医药集团有限公司 | 抗pd-1抗体及其用途 |
| PL3589754T3 (pl) * | 2017-03-01 | 2023-10-09 | F. Hoffmann-La Roche Ag | Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych |
| UA129583C2 (uk) * | 2017-03-06 | 2025-06-11 | Мерк Патент Гмбх | Водний фармацевтичний склад, який містить антитіло проти pd-l1 авелумаб |
| US20200115451A1 (en) * | 2017-03-31 | 2020-04-16 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody |
| CA3063201A1 (en) | 2017-05-09 | 2018-11-15 | Tesaro, Inc. | Combination therapies for treating cancer |
| CN106963948A (zh) * | 2017-05-12 | 2017-07-21 | 顾艳宏 | 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用 |
| RU2766590C2 (ru) | 2017-05-16 | 2022-03-15 | Цзянсу Хэнжуй Медисин Ко., Лтд. | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение |
| PL3630112T3 (pl) * | 2017-06-02 | 2024-07-01 | Bayer Healthcare Llc | Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu |
| JP7423511B2 (ja) * | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
| US11351163B2 (en) * | 2017-09-29 | 2022-06-07 | Bristol-Myers Squibb Company | Compositions and methods of treating cancer |
| KR20200071097A (ko) * | 2017-10-13 | 2020-06-18 | 메르크 파텐트 게엠베하 | Parp 억제제 및 pd-1 축 결합 길항제의 조합 |
| TW201923089A (zh) | 2017-11-06 | 2019-06-16 | 美商建南德克公司 | 癌症之診斷及治療方法 |
| WO2019096194A1 (zh) * | 2017-11-16 | 2019-05-23 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 |
| TW201938165A (zh) * | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| EP4349411A3 (en) | 2018-06-20 | 2024-06-19 | Incyte Corporation | Anti-pd-1 antibodies and uses thereof |
| AU2019288728A1 (en) | 2018-06-23 | 2021-01-14 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
| JP2021530502A (ja) | 2018-07-18 | 2021-11-11 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法 |
| WO2020015722A1 (en) * | 2018-07-19 | 2020-01-23 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-pd-1 antibodies, dosages and uses thereof |
| CN112805267B (zh) | 2018-09-03 | 2024-03-08 | 豪夫迈·罗氏有限公司 | 用作tead调节剂的甲酰胺和磺酰胺衍生物 |
| CA3116324A1 (en) * | 2018-10-18 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
| CA3115798A1 (en) * | 2018-10-31 | 2020-05-07 | Genentech, Inc. | Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor |
| US20220000858A1 (en) * | 2018-11-05 | 2022-01-06 | Aveo Pharmaceuticals, Inc. | Use of tivozanib to treat subjects with refractory cancer |
| BR112021007836A2 (pt) * | 2018-11-06 | 2021-08-10 | Jiangsu Hengrui Medicine Co., Ltd. | uso de anticorpo anti-pd-1 em combinação com famitinibe na preparação de medicamentos para o tratamento de tumores |
| AU2020208193A1 (en) | 2019-01-14 | 2021-07-29 | BioNTech SE | Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine |
| TW202043291A (zh) | 2019-04-19 | 2020-12-01 | 美商建南德克公司 | 抗mertk抗體及使用方法 |
| JP7629916B2 (ja) | 2019-11-13 | 2025-02-14 | ジェネンテック， インコーポレイテッド | 治療用化合物および使用方法 |
| EP4096708A1 (en) | 2020-01-31 | 2022-12-07 | Genentech, Inc. | Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine |
| TW202202138A (zh) | 2020-03-25 | 2022-01-16 | 美商歐克萊製藥公司 | 含有酪胺酸激酶抑制劑之眼用植入物 |
| JPWO2022004760A1 (enExample) | 2020-06-30 | 2022-01-06 | ||
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| JP2023542093A (ja) | 2020-09-09 | 2023-10-05 | 深▲セン▼微芯生物科技股▲フン▼有限公司 | 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 |
| TW202233671A (zh) | 2020-10-20 | 2022-09-01 | 美商建南德克公司 | Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法 |
| WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
| AU2021374592A1 (en) | 2020-11-04 | 2023-06-01 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| JP7762198B2 (ja) | 2020-11-04 | 2025-10-29 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び抗ｃｄ７９ｂ抗体薬物コンジュゲートによる処置のための投与 |
| EP4240766A2 (en) | 2020-11-04 | 2023-09-13 | Genentech, Inc. | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
| MX2023006488A (es) | 2020-12-02 | 2023-06-20 | Genentech Inc | Procedimientos y composiciones para el tratamiento neoadyuvante y adyuvante del carcinoma urotelial. |
| AU2021443318A1 (en) | 2021-04-30 | 2023-09-07 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| JP2024516230A (ja) | 2021-04-30 | 2024-04-12 | ジェネンテック， インコーポレイテッド | がんのための治療及び診断方法並びに組成物 |
| WO2022247846A1 (zh) * | 2021-05-26 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途 |
| JP2024525381A (ja) | 2021-07-02 | 2024-07-12 | ジェネンテック， インコーポレイテッド | がんを治療するための方法及び組成物 |
| CA3227334A1 (en) * | 2021-07-28 | 2023-02-02 | Tiumbio Co., Ltd. | Pharmaceutical composition for preventing or treating tumor, and use thereof |
| EP4377351A1 (en) | 2021-07-28 | 2024-06-05 | F. Hoffmann-La Roche AG | Methods and compositions for treating cancer |
| EP4377350A2 (en) | 2021-07-28 | 2024-06-05 | Genentech, Inc. | Methods and compositions for treating cancer |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| US12275745B2 (en) | 2021-11-24 | 2025-04-15 | Genentech, Inc. | Therapeutic compounds and methods of use |
| WO2023097195A1 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
| WO2023134787A2 (zh) * | 2022-01-14 | 2023-07-20 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 |
| US20250188147A1 (en) * | 2022-03-04 | 2025-06-12 | Panalos Bioscience, Inc. | Composition for combi-therapy comprising vegf-grab and pd-1 or pd-l1 antagonist |
| EP4504780A1 (en) | 2022-04-01 | 2025-02-12 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| KR20250008898A (ko) | 2022-05-11 | 2025-01-16 | 제넨테크, 인크. | 항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법 |
| CN119856056A (zh) | 2022-06-07 | 2025-04-18 | 基因泰克公司 | 用于确定包括抗pd-l1拮抗剂和抗tight拮抗剂抗体的肺癌治疗的疗效的方法 |
| KR20250039386A (ko) | 2022-07-13 | 2025-03-20 | 제넨테크, 인크. | 항-fcrh5/항-cd3 이중특이적 항체를 이용한 치료를 위한 투약법 |
| JP2025523845A (ja) | 2022-07-19 | 2025-07-25 | ジェネンテック， インコーポレイテッド | 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬 |
| CN120153254A (zh) | 2022-09-01 | 2025-06-13 | 基因泰克公司 | 膀胱癌的治疗和诊断方法 |
| WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
| EP4599089A1 (en) | 2022-10-05 | 2025-08-13 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
| TW202426505A (zh) | 2022-10-25 | 2024-07-01 | 美商建南德克公司 | 癌症之治療及診斷方法 |
| KR20250122520A (ko) | 2022-12-20 | 2025-08-13 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 rna 백신을 이용한 췌장암 치료 방법 |
| IL322360A (en) | 2023-04-11 | 2025-09-01 | Ocular Therapeutix Inc | Intraocular implant containing axitinib iv polymorph |
| WO2024218649A2 (en) * | 2023-04-17 | 2024-10-24 | Aurigene Oncology Limited | Combination of a protein kinase inhibitor with immunomodulatory agents |
| WO2024233341A1 (en) | 2023-05-05 | 2024-11-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| WO2024233646A1 (en) | 2023-05-10 | 2024-11-14 | Genentech, Inc. | Methods and compositions for treating cancer |
| WO2024263195A1 (en) | 2023-06-23 | 2024-12-26 | Genentech, Inc. | Methods for treatment of liver cancer |
| WO2024263904A1 (en) | 2023-06-23 | 2024-12-26 | Genentech, Inc. | Methods for treatment of liver cancer |
| TW202502813A (zh) * | 2023-06-30 | 2025-01-16 | 美商默沙東有限責任公司 | 包含偶聯物的藥物組合的治療方法和用途 |
| WO2025024257A1 (en) | 2023-07-21 | 2025-01-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| WO2025049277A1 (en) | 2023-08-25 | 2025-03-06 | Genentech, Inc. | Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist |
| WO2025085404A1 (en) | 2023-10-16 | 2025-04-24 | Genentech, Inc. | Diagnostic and therapeutic methods for treating lung cancer |
| WO2025155607A1 (en) | 2024-01-16 | 2025-07-24 | Genentech, Inc. | Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| KR100483494B1 (ko) | 1998-12-01 | 2005-04-15 | 프로테인 디자인 랩스 인코포레이티드 | 감마 인터페론에 대한 인간화 항체 |
| US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| EP2243493A1 (en) | 2002-07-03 | 2010-10-27 | Ono Pharmaceutical Co., Ltd. | Immunopotentiative composition |
| US6778740B2 (en) * | 2002-07-31 | 2004-08-17 | Agilent Technologies, Inc. | Alignment of optical fiber elements |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| EP1613320A1 (en) | 2003-04-03 | 2006-01-11 | Pfizer Inc. | Dosage forms comprising ag013736 |
| CN101094836A (zh) | 2004-11-02 | 2007-12-26 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
| CN101052633A (zh) | 2004-11-02 | 2007-10-10 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
| RU2007116150A (ru) | 2004-11-02 | 2008-11-10 | Пфайзер Инк. (US) | Полиморфные формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-[пиридин-2-ил)этенил]индазола |
| WO2006048745A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Inc. | Methods for preparing indazole compounds |
| KR20070058690A (ko) | 2004-11-02 | 2007-06-08 | 화이자 인코포레이티드 | 인다졸 화합물의 제조방법 |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| WO2006123223A1 (en) | 2005-05-19 | 2006-11-23 | Pfizer Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| US20100055111A1 (en) * | 2007-02-14 | 2010-03-04 | Med. College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
| WO2008122858A2 (en) | 2007-04-05 | 2008-10-16 | Pfizer Products Inc. | Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals |
| SI2170959T1 (sl) * | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| WO2011110604A1 (en) | 2010-03-11 | 2011-09-15 | Ucb Pharma, S.A. | Pd-1 antibody |
| PL2691112T3 (pl) * | 2011-03-31 | 2018-09-28 | Merck Sharp & Dohme Corp. | Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane |
| CN103857699B (zh) | 2011-05-24 | 2016-08-31 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
| TW202114735A (zh) | 2011-08-01 | 2021-04-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| TW201328725A (zh) | 2011-09-30 | 2013-07-16 | Pfizer | Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物 |
| RU2014116407A (ru) | 2011-11-11 | 2015-12-20 | Пфайзер Инк. | N-метил-2-[3-((e)-2-пиридин-2-ил-винил)-1н-индазол-6-илсульфанил]-бензамид для лечения хронического миелоидного лейкоза |
| CN105457021A (zh) * | 2012-05-04 | 2016-04-06 | 辉瑞公司 | 前列腺相关抗原及基于疫苗的免疫治疗疗法 |
| WO2013181452A1 (en) | 2012-05-31 | 2013-12-05 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| EP2981281B1 (en) | 2013-04-03 | 2020-07-15 | IBC Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| WO2015069266A1 (en) | 2013-11-07 | 2015-05-14 | Flynn Daniel L | Methods for inhibiting tie2 kinase useful in the treatment of cancer |
| CN105934253A (zh) | 2013-12-17 | 2016-09-07 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| DK3102605T3 (en) * | 2014-02-04 | 2019-02-25 | Pfizer | COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATMENT OF CANCER |
| WO2015126903A1 (en) | 2014-02-18 | 2015-08-27 | Health Research, Inc. | Combination therapy for hepatocellular carcinoma |
| CN106255510A (zh) | 2014-03-05 | 2016-12-21 | 百时美施贵宝公司 | 使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌 |
| US9649309B2 (en) | 2014-04-11 | 2017-05-16 | The University Of North Carolina At Chapel Hill | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity |
| RU2695332C2 (ru) | 2014-05-15 | 2019-07-23 | Бристол-Маерс Сквибб Компани | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства |
| WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
| AU2015314756A1 (en) | 2014-09-13 | 2017-03-16 | Novartis Ag | Combination therapies of alk inhibitors |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
| WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| WO2016069727A1 (en) | 2014-10-29 | 2016-05-06 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| GB201421647D0 (en) | 2014-12-05 | 2015-01-21 | Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie | CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
-
2015
- 2015-02-03 DK DK15703439.8T patent/DK3102605T3/en active
- 2015-02-03 ES ES15703439T patent/ES2710211T3/es active Active
- 2015-02-03 PT PT15703439T patent/PT3102605T/pt unknown
- 2015-02-03 TW TW104103603A patent/TWI663983B/zh active
- 2015-02-03 CA CA2937521A patent/CA2937521C/en active Active
- 2015-02-03 SI SI201530602T patent/SI3102605T1/sl unknown
- 2015-02-03 US US15/115,730 patent/US10570202B2/en active Active
- 2015-02-03 EA EA201691376A patent/EA201691376A1/ru unknown
- 2015-02-03 KR KR1020237003437A patent/KR20230023810A/ko not_active Ceased
- 2015-02-03 IL IL311399A patent/IL311399A/en unknown
- 2015-02-03 JP JP2016549715A patent/JP6591428B2/ja active Active
- 2015-02-03 CA CA3210360A patent/CA3210360A1/en active Pending
- 2015-02-03 CN CN201580007146.1A patent/CN105960415A/zh active Pending
- 2015-02-03 CN CN202410389501.7A patent/CN118286440A/zh active Pending
- 2015-02-03 PL PL18205542T patent/PL3498734T3/pl unknown
- 2015-02-03 SG SG10201806656UA patent/SG10201806656UA/en unknown
- 2015-02-03 PL PL15703439T patent/PL3102605T3/pl unknown
- 2015-02-03 SG SG11201605824XA patent/SG11201605824XA/en unknown
- 2015-02-03 EP EP21187795.6A patent/EP3971209A1/en active Pending
- 2015-02-03 EP EP18205542.6A patent/EP3498734B1/en not_active Revoked
- 2015-02-03 HU HUE15703439A patent/HUE041469T2/hu unknown
- 2015-02-03 AU AU2015214390A patent/AU2015214390B2/en active Active
- 2015-02-03 PT PT182055426T patent/PT3498734T/pt unknown
- 2015-02-03 EP EP15703439.8A patent/EP3102605B1/en not_active Revoked
- 2015-02-03 KR KR1020257022562A patent/KR20250109796A/ko active Pending
- 2015-02-03 HU HUE18205542A patent/HUE057205T2/hu unknown
- 2015-02-03 TR TR2019/01507T patent/TR201901507T4/tr unknown
- 2015-02-03 BR BR112016017256A patent/BR112016017256A2/pt not_active Application Discontinuation
- 2015-02-03 MX MX2016010082A patent/MX386604B/es unknown
- 2015-02-03 SI SI201531757T patent/SI3498734T1/sl unknown
- 2015-02-03 KR KR1020167024007A patent/KR20160108566A/ko not_active Ceased
- 2015-02-03 WO PCT/US2015/014212 patent/WO2015119930A1/en not_active Ceased
- 2015-02-03 ES ES18205542T patent/ES2899457T3/es active Active
-
2016
- 2016-07-13 IL IL246760A patent/IL246760A0/en unknown
-
2019
- 2019-02-01 CY CY20191100147T patent/CY1121374T1/el unknown
- 2019-09-19 JP JP2019170177A patent/JP6894952B2/ja active Active
-
2020
- 2020-01-14 US US16/742,657 patent/US20200325228A1/en not_active Abandoned
-
2021
- 2021-06-03 JP JP2021093346A patent/JP2021130709A/ja active Pending
- 2021-11-29 CY CY20211101042T patent/CY1124785T1/el unknown
-
2022
- 2022-04-20 US US17/725,240 patent/US20220324979A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506227A5 (enExample) | ||
| JP2017530950A5 (enExample) | ||
| RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
| Henricks et al. | The use of combinations of monoclonal antibodies in clinical oncology | |
| Nagelkerke et al. | Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy | |
| Sun et al. | Multiple roles of autophagy in the sorafenib resistance of hepatocellular carcinoma | |
| JP2019506403A5 (enExample) | ||
| JP2018512391A5 (enExample) | ||
| Du et al. | Integration of molecular targeted therapy with radiation in head and neck cancer | |
| US11220548B2 (en) | Treatment of C1013G/CXCR4-associated Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody | |
| JP2018524347A5 (enExample) | ||
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| JP2010515709A5 (enExample) | ||
| JP6464085B2 (ja) | 神経膠芽腫の治療のための併用療法 | |
| Flinn et al. | Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia | |
| JP2018522850A5 (enExample) | ||
| RU2018101314A (ru) | Комбинированные способы лечения антагонистами pd-l1 | |
| JP2017537070A5 (enExample) | ||
| JP2018508516A5 (enExample) | ||
| Jamil et al. | Tivozanib: status of development | |
| JP2019081799A (ja) | オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用 | |
| Klintmalm et al. | The role of mammalian target of rapamycin inhibitors in the management of post‐transplant malignancy | |
| JP2017510661A5 (enExample) |